DeepSyte matches this bill to the issues you care about and shows whether your reps' votes line up — not party, not press releases. Take the 2-minute values quiz to see your alignment.
Sign in and take the values quiz to see how this bill lines up with what you've said.
Based on the bill's title, this measure would amend the Public Health Service Act to establish that biosimilar biological products do not require clinical studies assessing pharmacodynamics or comparative clinical efficacy as a default condition for licensure. The bill would modify regulatory standards for how the FDA evaluates biosimilar drugs, potentially streamlining the approval pathway by reducing required clinical testing.
Sign in and take the values quiz to get a personalized read on how this bill lines up with your positions.
Sign in to see how your representatives voted on this bill.